| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5825787 | Clinical Therapeutics | 2012 | 16 Pages |
Abstract
Despite the limitations of restricted availability of clinical data and uncertainty regarding the price of generic zoledronic acid, the findings from the present analysis suggest that the use of denosumab is associated with a high ICER compared with zoledronic acid. This finding may raise important questions regarding the economic value of denosumab in bone-metastatic breast cancer.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Sonya J. PhD, John A. BA, Satyin MSci, MBA, Marc F. MSc, MA,